Summary
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
History
Celularity was founded in 2018 by Dr. Bob Hariri to utilize the therapeutic potential of the unexplored biological capacities of the cells derived from the placenta. Since its founding, Celularity has become one of the most respected leaders in the therapeutic field of regenerative medicine.
Mission
Celularity is committed to developing safe, efficient, and accessible cellular therapies that have the power to improve and save lives.
Vision
Our vision is to create a world where post-natal cellular therapies are available for individuals with a variety of medical conditions and diseases.
Key Team
Dr. Bradley Glover Ph.D. (Exec. VP & COO)
Mr. Tim Wilk (Sr. VP of Technical Operations)
Carlos Ramirez (SVP of Investor Relations)
Mr. Keary R. Dunn Esq. (EVP, Gen. Counsel, Chief Legal Officer & Head of Bus. Devel.)
Ms. Beth Steinbrenner (Exec. VP of HR)
Dr. Stephen A. Brigido D.P.M. (Pres of Degenerative Diseases)
Dr. Anne Jones Ph.D. (Exec. VP & Chief Bus. Officer)
Recognition and Awards
Celularity has won numerous awards and recognitions, including the Wall Street Journal Innovation Award, the Global Entrepreneur Award, and the Breakthrough Prize in Life Science.
References
United States 